Contributor: Special thanks to Dipak Kotecha
Based on the ESC Clinical Practice Guidelines on Atrial Fibrillation (Management of) 2016
Webinars on this topic
ESC webinar on "New ESC guidelines for atrial fibrillation: future trends for AF and its neurological complications, the impact of anticoagulation and ablation" streamed live on 15 December 2016: Watch the recording.
Part 1 - Overview of the Guidelines
| Session title |
Slides |
Webcast |
| ESC Clinical Practice Guidelines: Atrial fibrillation - Part 1 |
|
|
| ESC Clinical Practice Guidelines: Atrial fibrillation - Part 2 |
|
|
| First presentation of atrial fibrillation: Initial approach, goals, and expectations |
|
|
| The atrial fibrillation heart team approach to stroke prevention: risk stratification and stroke prevention |
|
|
| The atrial fibrillation heart team approach to stroke prevention: managing complications |
|
|
| The atrial fibrillation heart team approach to rate control |
|
|
| The atrial fibrillation heart team approach to antiarrhythmic drugs and catheter ablation |
|
|
| The atrial fibrillation heart team approach to atrial fibrillation surgery |
|
|
| Meet the Guidelines Task Force - Atrial fibrillation |
|
|
Part 2 - Topics in focus
| Topic/Section |
Session title |
Slides |
Webcast |
| Screening for atrial fibrillation to prevent stroke |
Atrial fibrillation Symposium joint with the Lancet |
|
|
| Rate control |
Atrial fibrillation Symposium joint with the Lancet |
|
|
| Treating low-risk patients with nonvalvular AF |
Risk profiles for patients with atrial fibrillation and the quality of stroke prevention: results from the GARFIELD-AF registry |
|
|
| Early mortality in newly diagnosed nonvalvular AF |
Risk profiles for patients with atrial fibrillation and the quality of stroke prevention: results from the GARFIELD-AF registry |
|
|
| State of the art in catheter ablation of atrial fibrillation |
Can we maintain sinus rhythm by catheter ablation? |
|
|
| Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation? |
Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR |
|
|
| ESC-EURObservational Research Programme: In-hospital and 1-year follow-up of the Long-term Atrial Fibrillation Ablation Registry, Conducted by the European Heart Rhythm Association |
Registries atrial fibrillation |
|
|
| Association of Inappropriate Dosing of Non-Vitamin K Oral Anticoagulants and Risk of Adverse Events: Results from the ORBIT-AF II Registry |
Registries atrial fibrillation |
|
|
| State of the art in treatment of acute coronary syndrome patients in need of oral anticoagulation |
Challenges with anticoagulants and antithrombotics in acute coronary syndrome |
|
|
| How to define non-valvular atrial fibrillation? |
Atrial fibrillation in clinical practice |
|
|
| Heart failure and atrial fibrillation: which comes first? |
Atrial fibrillation in clinical practice |
|
|
| The AF epidemic and AF ablation treatment options in 2016: a clinical evidence review |
Creating a new landscape in AF ablation and the impact on clinical practice |
|
|
| Management of atrial fibrillation: the new European Society of Cardiology 2016 Guidelines |
Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications |
|
|
| Anticoagulation in patients with atrial fibrillation: challenges with continuing protection from hospital to home |
Practical management of patients with atrial fibrillation – Individualised approaches to stroke prevention |
|
|
| Day-to-day management of patients with atrial fibrillation on non-VKA oral anticoagulant therapy – Practical perspectives |
Interpreting findings with non-vitamin K antagonist (VKA) oral anticoagulants in atrial fibrillation |
|
|
| Gender differences in clinical presentation and predictors of one-year outcomes in atrial fibrillation |
Clinical features and management of atrial fibrillation |
|
|
| Ideal AF ablation candidate and when do I refer? |
Creating a new landscape in AF ablation and the impact on clinical practice |
|
|
| The management of patients with atrial fibrillation and renal impairment – Practical perspectives |
Interpreting findings with non-vitamin K antagonist (VKA) oral anticoagulants in atrial fibrillation |
|
|
Clinical cases on this topic
Our mission: To reduce the burden of cardiovascular disease.